ALLO · CIK 1737287
What Allogene Therapeutics, Inc. told the SEC could break it.
Allogene's disclosures describe a pre-revenue cell-therapy company whose footing depends on capital it hasn't yet earned: it has no approved products and no product sales, keeps incurring significant R&D and operating losses, and relies on raising additional capital through equity to fund operations. Its CAR-T manufacturing leans on raw materials available only from a single supplier or a small number of suppliers — vendors that could exit or be bought by a competitor — and even with approval, future U.S. economics are exposed to drug-pricing reform, including a 'Most-Favored-Nation' policy that could sharply cut U.S. list prices.
3 self-disclosed vulnerabilities, pulled from its own filings, each in the company’s words, with the source. This is the risk register almost nobody reads.
In its own words
What could break it.
Liquidity & debt
- Pre-revenue capital dependence / continuing operating lossesmedium
Allogene has no approved products and no product revenue, continues to incur significant R&D and operating losses, and depends on raising additional capital (ATM, equity offerings) to fund operations.
“we have no products approved for commercial sale and have not generated any revenue from product sales to date, and we will continue to incur significant research and development and other expenses related to our ongoing operations.”
SEC filing →As of 2026
Regulatory & policy
- U.S. drug-pricing reform (Most-Favored-Nation pricing)medium
A 'Most-Favored-Nation' drug pricing policy referencing the lowest ex-U.S. list price, if applied to any approved Allogene product, could significantly cut U.S. list prices and reduce the company's U.S. market opportunity.
“a “Most-Favored-Nation” pricing policy that is determined to apply to us and any of our products that receives regulatory approval based on a reference to the lowest ex-U.S. list price for such products, could significantly reduce the U.S. list price for such products and likewise reduce our annual market opportunity in the United States.”
Supplier concentration
- Single/limited-source raw materials for cell-therapy manufacturingmedium
Some raw materials for its CAR-T manufacturing are available only from a single supplier or a small number of suppliers, and competition from other cell-therapy companies makes securing materials on reasonable terms uncertain.
“Some raw materials are currently available from a single supplier, or a small number of suppliers. We cannot be sure that these suppliers will remain in business or that they will not be purchased by one of our competitors or another company that is not interested in continuing to produce these materials for our intended purpose.”
SEC filing →As of 2026
The hidden graph
Who it depends on, and who depends on it.
Relationships surfaced from filings, including ones disclosed by the other side, which is how the non-obvious ones come to light.
Its suppliers
“Cellectis and Arbor are our sole sources for this technology, including for certain tools such as nucleases and vectors.”
Cited →Arbor Biotechnologies
“Cellectis and Arbor are our sole sources for this technology, including for certain tools such as nucleases and vectors.”
Cited →Foresight Diagnostics
“Under the Foresight Agreement, the Company has agreed to use its commercially reasonable efforts to obtain regulatory approval of cema-cel, and Foresight Diagnostics has agreed to use its commercially reasonable efforts to obtain regulatory approval of its CLARITY TM MRD assay for use as an in vitro diagnostic with cema-cel.”
Cited →
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch